Mission Wealth Management LP Buys 621 Shares of Sanofi (NASDAQ:SNY)

Mission Wealth Management LP lifted its stake in Sanofi (NASDAQ:SNY) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,748 shares of the company’s stock after buying an additional 621 shares during the period. Mission Wealth Management LP’s holdings in Sanofi were worth $374,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Synergy Asset Management LLC bought a new stake in shares of Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. lifted its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the period. Sunbelt Securities Inc. lifted its stake in shares of Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares during the period. Sierra Ocean LLC bought a new position in Sanofi during the fourth quarter worth about $44,000. Finally, Versant Capital Management Inc bought a new position in Sanofi during the fourth quarter worth about $54,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Performance

NASDAQ:SNY opened at $59.15 on Thursday. Sanofi has a 1 year low of $45.22 and a 1 year high of $59.19. The firm has a 50 day moving average of $52.22 and a 200-day moving average of $52.68. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $150.11 billion, a P/E ratio of 23.76, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.